Overview

12-month Study of AMG 073 in Renal Osteodystrophy

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
4 doses of AMG 073 or placebo over 52 weeks after a 30-day screening period. Throughout the study, labs will be drawn to measure analytes such as iPTH and corrected calcium. In addition, a bone biopsy will be performed at screening and at the end of study.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Cinacalcet
Cinacalcet Hydrochloride